Across TCGA pan-cancer cohorts, BANF2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BANF2 data layer compared with 17 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BANF2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BANF2 expression acts as an unfavorable survival marker.
PDAC are the cancer types where BANF2 mass-spec protein most reproducibly stratifies survival.